Cargando…

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up

INTRODUCTION: To evaluate the oncological outcome of high dose rate (HDR) brachytherapy (BRT) as monotherapy for clinically localised prostate cancer (PCA). MATERIAL AND METHODS: Between January 2002 and February 2004, 141 consecutive patients with clinically localised PCA were treated with HDR-BRT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behmueller, Manuel, Tselis, Nikolaos, Zamboglou, Nikolaos, Zoga, Eleni, Baltas, Dimos, Rödel, Claus, Chatzikonstantinou, Georgios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674679/ https://www.ncbi.nlm.nih.gov/pubmed/34926278 http://dx.doi.org/10.3389/fonc.2021.770959

Ejemplares similares

Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
por: Chatzikonstantinou, Georgios, et al.
Publicado: (2019)

High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
por: Tselis, Nikolaos, et al.
Publicado: (2013)

Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme
por: Archavlis, Eleftherios, et al.
Publicado: (2013)

Factors Associated with Hemorrhage of Melanoma Brain Metastases after Stereotactic Radiosurgery in the Era of Targeted/Immune Checkpoint Inhibitor Therapies
por: Zoga, Eleni, et al.
Publicado: (2022)

Interstitial multicatheter HDR-brachytherapy as accelerated partial breast irradiation after second breast-conserving surgery for locally recurrent breast cancer
por: Chatzikonstantinou, Georgios, et al.
Publicado: (2021)

Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Radioimmunotherapy: future prospects from the perspective of brachytherapy
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy
por: Scherf, Christian, et al.
Publicado: (2022)

Individualized mould-based high-dose-rate brachytherapy for perinasal skin tumors: technique evaluation from a dosimetric point of view
por: Scherf, Christian, et al.
Publicado: (2021)

Radiobiological evaluation of the influence of dwell time modulation restriction in HIPO optimized HDR prostate brachytherapy implants
por: Mavroidis, Panayiotis, et al.
Publicado: (2010)

Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer
por: Tselis, Nikolaos, et al.
Publicado: (2019)

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy
por: Fleischmann, Max, et al.
Publicado: (2019)

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome
por: Strouthos, Iosif, et al.
Publicado: (2021)

Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

Comprehensive brachytherapy: physical and clinical aspects
por: Venselaar, Jack L M, et al.
Publicado: (2013)

Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors
por: Karagiannis, Efstratios, et al.
Publicado: (2022)

Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition
por: Sachpazidis, Ilias, et al.
Publicado: (2020)

Brachytherapy for Prostate Cancer: A Systematic Review
por: Koukourakis, Georgios, et al.
Publicado: (2009)

New (125)I brachytherapy source IsoSeed I25.S17plus: Monte Carlo dosimetry simulation and comparison to sources of similar design
por: Pantelis, Evaggelos, et al.
Publicado: (2013)

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
por: Johansson, Bengt, et al.
Publicado: (2021)

Oncological and urinary outcomes following low‐dose‐rate brachytherapy with a median follow‐up of 11.8 years
por: Yaxley, William John, et al.
Publicado: (2022)

BiopSee(®) – transperineal stereotactic navigated prostate biopsy
por: Zogal, Pawel, et al.
Publicado: (2011)

A detailed dosimetric comparison between manual and inverse plans in HDR intracavitary/interstitial cervical cancer brachytherapy
por: Trnková, Petra, et al.
Publicado: (2011)

Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference
por: Zamboglou, Constantinos, et al.
Publicado: (2019)

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
por: Yoshioka, Yasuo, et al.
Publicado: (2013)

High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
por: Yoshioka, Yasuo, et al.
Publicado: (2014)

Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer
por: Contreras, Jessika A., et al.
Publicado: (2015)

Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience
por: Barnes, Justin M., et al.
Publicado: (2019)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

Dosimetric Impact of Interfractional Variations for Post-prostatectomy Radiotherapy to the Prostatic Fossa—Relevance for the Frequency of Position Verification Imaging and Treatment Adaptation
por: Splinter, Mona, et al.
Publicado: (2019)

Eine Monotherapie mit Immuncheckpointblockade führt bei Patienten mit Rektumkarzinom und Mikrosatelliteninstabilität zur klinischen Komplettremission
por: Diefenhardt, Markus, et al.
Publicado: (2022)

High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
por: Cendales, Ricardo, et al.
Publicado: (2015)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
por: Barnes, Justin, et al.
Publicado: (2019)

Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy – A Voxel-by-Voxel Analysis
por: Splinter, Mona, et al.
Publicado: (2020)

Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy—Implications for Imaging Frequency and Treatment Adaptation
por: Bostel, Tilman, et al.
Publicado: (2019)

Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM()
por: Kirisits, Christian, et al.
Publicado: (2014)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

Dose coverage comparison between “interstitial catheter-only” and “hybrid intracavitary-interstitial brachytherapy” for early stage squamous cell carcinoma of the buccal mucosa
por: Murakami, Naoya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cecmus91q8u8e9ila8fmuf86do